Patents Represented by Attorney John Alexander
-
Patent number: 8008263Abstract: The present application describes organic compounds that are useful for the treatment, prevention and/or amelioration of human diseases.Type: GrantFiled: October 10, 2008Date of Patent: August 30, 2011Assignee: Novartis AGInventors: Shawn D. Britt, Lech Andrzej Ciszewski, Jiping Fu, Subramanian Karur, Yugang Liu, Peichao Lu, David Thomas Parker, Mahavir Prashad, Prakash Raman, Pascal Rigollier, Mohindra Seepersaud, Aregahegn Yifru, Rui Zheng
-
Patent number: 7863314Abstract: Provided are 5-membered heterocycle-based p38 kinase inhibitors. Further provided are pyrazole and imidazole-based p38 kinase, including p38? and p38? kinase, inhibitors. Pharmaceutical compositions containing the compounds are also provided. Methods of use of the compounds and compositions are also provided, including methods of treatment, prevention, or amelioration of one or more symptoms of p38 kinase mediated diseases and disorders, including, but not limited to, inflammatory diseases and disorders.Type: GrantFiled: June 25, 2004Date of Patent: January 4, 2011Assignee: Novartis AGInventors: Olga M. Fryszman, Hengyuan Lang, Jiong Lan, Edcon Chang, Yunfeng Fang
-
Patent number: 7851439Abstract: Organic compounds that are useful for the treatment, prevention and/or amelioration of diseases are described.Type: GrantFiled: May 30, 2007Date of Patent: December 14, 2010Assignee: Novartis AGInventors: Simon Bushell, Matthew LaMarche, Michael J. Patane, Lewis Whitehead
-
Patent number: 7825152Abstract: The present application describes organic compounds that are useful for the treatment, prevention and/or amelioration of human diseases.Type: GrantFiled: April 9, 2007Date of Patent: November 2, 2010Assignee: Novartis AGInventors: Trixi Brandl, Jiping Fu, Francois Lenoir, David Thomas Parker, Michael Patane, Branko Radetich, Prakash Raman, Pascal Rigollier, Mohindra Seepersaud, Oliver Simic, Aregahegn Yifru, Rui Zheng
-
Patent number: 7820818Abstract: The invention provides compounds of formula I or a pharmaceutically acceptable salt or ester thereof wherein the symbols have meaning as defined, which are inhibitors of cathepsin K and find use pharmaceutically for treatment of diseases and medical conditions in which cathepsin K is implicated, e.g. various disorders including inflammation, rheumatoid arthritis, osteoarthritis, osteoporosis and tumors.Type: GrantFiled: March 6, 2009Date of Patent: October 26, 2010Assignee: Novartis AGInventors: Eva Altmann, Claudia Betschart, Kenji Hayakawa, Osamu Irie, Junichi Sakaki, Genji Iwasaki, Rene Lattmann, Martin Missbach, Naoki Teno
-
Patent number: 7795251Abstract: The present invention relates 3,4-dihydro-benzo[e][1,3]oxazin-2-ones which are substituted at the nitrogen atom by unsubstituted or substituted (C1-8)alkyl, (C3-8)cycloalkyl, (C3-8)cycloalkyl(C1-4)alkyl, (C6-18)aryl or (C6-18)aryl(C1-4)alkyl and their use as pharmaceuticals.Type: GrantFiled: April 13, 2006Date of Patent: September 14, 2010Assignee: Novartis AGInventors: Andreas Billich, Hubert Gstach, Philipp Lehr
-
Patent number: 7781481Abstract: N-(benzenesulphonyl)-2,3-dihydro-1H-indols, wherein the indol is substituted by cyano, carboxy or alkylcarbonyloxy and their use as therapeutical agents.Type: GrantFiled: December 22, 2006Date of Patent: August 24, 2010Assignee: Novartis AGInventors: Jose M. Carballido Herrera, Herbert Jaksche, Philipp Lehr, Gudrun Werner, Anthony Winiski
-
Patent number: 7759390Abstract: Compounds of formula I, wherein one of R1 and R2 is thienyl which is substituted by halogen and the other of R1 and R2 is substituted phenyl, wherein the substituents are as defined in the claims, with the proviso that the phenyl group is substituted by at least a cyano, carboxy or (C1-4)alkyloxycarbonyl group, are inhibitors of CCR9 activity and useful for therapeutic treatment.Type: GrantFiled: December 22, 2006Date of Patent: July 20, 2010Assignee: Novartis AGInventors: Jose M. Carballido Herrera, Herbert Jaksche, Philipp Lehr, Gudrun Werner, Anthony Winiski
-
Patent number: 7754758Abstract: Compounds of formula I in free or salt form, wherein T, X, Y, U, R1, R2, m, n and p have the meanings as indicated in the specification, are useful for treating conditions mediated by CCR3. Pharmaceutical compositions that contain the compounds and processes for preparing the compounds are also described.Type: GrantFiled: January 28, 2005Date of Patent: July 13, 2010Assignee: Novartis AGInventors: Gurdip Bhalay, Andrew Dunstan, Angela Glen, Trevor John Howe, Clive McCarthy
-
Patent number: 7754719Abstract: Compound of the formula (I) wherein R1, R2, n and m are as defined in the specification. The compounds of formula (I) are somatostatin sst1 receptor antagonists.Type: GrantFiled: July 13, 2006Date of Patent: July 13, 2010Assignee: Novartis AGInventors: Daniel Hoyer, Konstanze Hurth, Thomas J. Troxler
-
Patent number: 7705037Abstract: The present invention relates to compounds of formula (I). These compounds are a novel type of peptide deformylase (PDF) inhibitors, and are therefore of great interest especially as new antibiotics.Type: GrantFiled: June 6, 2006Date of Patent: April 27, 2010Assignee: Novartis AGInventor: Michael Thormann
-
Patent number: 7696216Abstract: A compound of formula (I): wherein R1, R2, R3 and Y are as defined herein, or a pharmaceutically-acceptable and -cleavable ester, or acid addition salt thereof, useful for promoting the release of parathyroid hormone, e.g. for preventing or treating bone conditions which are associated with increased calcium depletion or resorption or in which stimulation of bone formation and calcium fixation in the bone is desirable.Type: GrantFiled: December 22, 2003Date of Patent: April 13, 2010Assignee: Novartis AGInventors: Eva Altmann, Rene Beerli, Marc Gerspacher, Johanne Renaud, Sven Weiler, Leo Widler
-
Patent number: 7691841Abstract: Compounds of formula I in free or salt form, wherein Ar, X, Y and T have the meanings as indicated in the specification, are useful for treating a condition mediated by CCR-3, particularly an inflammatory or allergic condition such as an inflammatory or obstructive airways disease. Pharmaceutical compositions that contain the compounds and processes for preparing the compounds are also described.Type: GrantFiled: August 9, 2005Date of Patent: April 6, 2010Assignee: Novartis AGInventor: Darren M Legrand
-
Patent number: 7687637Abstract: Compounds of formula I in free or salt form, wherein R1, R2, R3, R4 and R5 have the meanings as indicated in the specification, are useful for treating diseases mediated by phosphatidylinositol 3-kinase. Pharmaceutical compositions that contain the compounds and processes for preparing the compounds are also described.Type: GrantFiled: February 27, 2003Date of Patent: March 30, 2010Assignee: Novartis AGInventors: Ian Bruce, Peter Finan, Catherine Leblanc, Clive McCarthy, Lewis Whitehead, Nicola Press, Graham Charles Bloomfield, Judy Hayler, Louise Kirman, Mrinalini Sachin Oza, Lena Shukla
-
Patent number: 7662833Abstract: The present invention relates to compounds of formula (I). These compounds are a novel type of peptide deformylase (PDF) inhibitors, and are therefore of great interest especially as new antibiotics.Type: GrantFiled: April 24, 2006Date of Patent: February 16, 2010Assignee: Novartis AGInventor: Michael Thormann
-
Patent number: 7659293Abstract: The invention relates to ?-amino-N-hydroxy-acetamide derivatives of formula I, wherein R is di-lower alkyl amino, 1,2,3-triazol-1-yl, 1,2,3-triazol-2-yl or 1,2,4-triazol-4-yl, m represents an integer from 1 up to and including 10, and n represents an integer from 0 up to and including 10, and salts thereof: to processes for their preparation, pharmaceutical compositions comprising said hydroxamic acid derivatives, the use of such hydroxamic acid derivatives as medicaments, and a method of treating conditions or diseases mediated by matrix-degrading metalloproteinases (MMP's) using said derivatives alone or in combination with one or more other therapeutic agents.Type: GrantFiled: October 5, 2007Date of Patent: February 9, 2010Assignee: Novartis AGInventors: Kenji Hayakawa, Genji Iwasaki, Shinichi Koizumi, Ichiro Umemura
-
Patent number: 7544688Abstract: The invention provides compounds of Formula (I) or a pharmaceutically acceptable salt or ester thereof wherein the symbols have meaning as defined, which are inhibitors of cathepsin K and find use pharmaceutically for treatment of diseases and medical conditions in which cathepsin K is implicated, e.g. various disorders including inflammation, rheumatoid arthritis, osteoarthritis, osteoporosis and tumors.Type: GrantFiled: August 29, 2003Date of Patent: June 9, 2009Assignee: Novartis AGInventors: Eva Altmann, Claudia Betschart, Kenji Hayakawa, Osamu Irie, Junichi Sakaki, Genji Iwasaki, Rene Lattmann, Martin Missbach, Naoki Teno
-
Patent number: 7531546Abstract: The invention provides compounds of formula (I) or a pharmaceutically acceptable salt or ester thereof formula (I) wherein the symbols have the meaning as defined in the description. Said compounds are inhibitors of cathepsin K and/or cathepsin S and are useful for the treatment of diseases and medical conditions in which cathepsin K and/or cathepsin S is implicated, e.g. various disorders including neuropathic pain, inflammation, rheumatoid arthritis, osteoarthritis, osteoporosis, multiple sclerosis and tumors.Type: GrantFiled: February 27, 2004Date of Patent: May 12, 2009Assignee: Novartis AGInventors: Osamu Irie, Genji Iwasaki, Keiichi Masuya, Takahiro Miyake, Naoki Teno